{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Favalli A"],"funding":["Regione Lombardia","Ministero della Salute","Fondazione Romeo ed Enrica Invernizzi"],"pubmed_abstract":["COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and the prolonged use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) DMARDs or biologic and targeted synthetic (b/ts) DMARDs. To provide an integrated analysis of the immune response following SARS-CoV-2 infection in RMD patients treated with different classes of DMARDs we carried out an immunological analysis of the antibody responses toward SARS-CoV-2 nucleocapsid and RBD proteins and an extensive immunophenotypic analysis of the major immune cell po"],"journal":["Frontiers in immunology"],"pagination":["873195"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9226581"],"repository":["biostudies-literature"],"pubmed_title":["Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations."],"pmcid":["PMC9226581"],"pubmed_authors":["Favalli EG","Fabbris T","Pesce E","Gobbini A","Caporali R","Maioli G","Granucci F","Bandera A","Favalli A","Sarnicola ML","De Francesco R","Donnici L","Gori A","Grifantini R","Martinovic M","Gruarin P","Notarbartolo S","Manganaro L","Curti S","Biggioggero M","Marongiu L","Abrignani S","Zagato E","Bevilacqua V","Bombaci M","Crosti M","Marchisio E"],"additional_accession":[]},"is_claimable":false,"name":"Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.","description":"COVID-19 has proven to be particularly serious and life-threatening for patients presenting with pre-existing pathologies. Patients affected by rheumatic musculoskeletal disease (RMD) are likely to have impaired immune responses against SARS-CoV-2 infection due to their compromised immune system and the prolonged use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) DMARDs or biologic and targeted synthetic (b/ts) DMARDs. To provide an integrated analysis of the immune response following SARS-CoV-2 infection in RMD patients treated with different classes of DMARDs we carried out an immunological analysis of the antibody responses toward SARS-CoV-2 nucleocapsid and RBD proteins and an extensive immunophenotypic analysis of the major immune cell po","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-27T20:19:28.973Z","creation":"2024-11-15T12:44:29.064Z"},"accession":"S-EPMC9226581","cross_references":{"pubmed":["35757699"],"doi":["10.3389/fimmu.2022.873195"]}}